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Background
Maintenance of vascular homeostasis depends on phe-
notypic switching of vascular smooth muscle cells
(VSMCs) during development, vascular injury repair,
and disease. In healthy blood vessels, VSMCs exhibit a
differentiated, ‘contractile’ phenotype, but in diseased
vascular tissue or after vascular injury, they de-differ-
entiate into a ‘synthetic’ state, characterized by
decreased smooth muscle (SM)-specific gene expression
and increased proliferation and motility [1].
Results
Although still controversial, a large number of studies
indicate that the NO/cGMP/PKGI pathway inhibits pro-
liferation and de-differentiation of VSMCs. Subcultured
primary VSMCs undergo de-differentiation to a ‘syn-
thetic’ phenotype with both reduced SM-specific gene
expression and loss of PKGI expression. A more ‘con-
tractile’ phenotype can be regained by restoring PKGI
[2]. PKGI stimulates SM-specific gene expression
through regulation of the cystein-rich LIM only protein
CRP4 that cooperates with SRF-containing transcription
complexes [3]. But the mechanism how cGMP/PKGI
regulates SM-specific phenotype is incompletely under-
stood. In C2C12 myoblasts, PKGI phosphorylates the
BMP type II receptor (BMPRII); in response to BMP-2,
PKGI dissociates from the receptor, associates with the
activated Smad1/4 complex, translocates to the nucleus,
and forms a complex with Smads and the general tran-
scription factor TFII-I to collaboratively activate tran-
scription [4]. In the vascular system, BMP signaling
inhibits proliferation and migration of VSMCs, and
upregulates SM-specific genes, through Smad-dependent
[5-8] and/or Smad-independent pathways [9-11]. Inter-
estingly, heterozygous germline mutations within
BMPRII can cause pulmonary arterial hypertension
(PAH), a disease characterized by thickening of pulmon-
ary arteries due to abnormal proliferation, migration,
and/or apoptosis of VSMCs and endothelial cells [12].
Considering these data we hypothesize that PKGI pro-
motes the differentiated ‘contractile’ phenotype of
VSMCs at least in part through enhancing vascular
BMP/Smad signaling. Indeed we found that cGMP/
PKGI promoted Smad1/5 activation and BMP target
gene expression in VSMCs and SM precursor cells.
Pharmacological or siRNA-mediated inhibition of the
NO/cGMP/PKGI pathway not only suppressed BMP-
induced upregulation of SM-specific gene transcription,
but also abrogated the anti-proliferative and anti-migra-
tory effects of BMP on VSMCs. Furthermore prelimin-
ary data suggest that Smad crosstalk with other
transcriptional regulators is involved.
Conclusion
Our data imply that within the vasculature, PKGI is a
critical regulator of the VSMC differentiation-promoting
effects of BMP. The integration of cGMP/PKGI pathway
into BMP/Smad signaling in the vascular system might
provide new insight into the mechanisms of vascular
remodeling in diseases such as atherosclerosis, vascular
restenosis and pulmonary hypertension.
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